Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
Given the recent Zika virus (ZIKV) epidemic, development of an effective vaccine is of high importance. Here, the authors use a licensed live-attenuated flavivirus vaccine backbone to develop a ZIKV vaccine and determine immunogenicity, safety and protection profiles in different animal models.
Guardado en:
Autores principales: | Xiao-Feng Li, Hao-Long Dong, Hong-Jiang Wang, Xing-Yao Huang, Ye-Feng Qiu, Xue Ji, Qing Ye, Chunfeng Li, Yang Liu, Yong-Qiang Deng, Tao Jiang, Gong Cheng, Fu-Chun Zhang, Andrew D. Davidson, Ya-Jun Song, Pei-Yong Shi, Cheng-Feng Qin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/788df413c3c54bebaab8d4b979a10833 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A single-dose live attenuated chimeric vaccine candidate against Zika virus
por: Wei-Xin Chin, et al.
Publicado: (2021) -
Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate
por: Qi Chen, et al.
Publicado: (2018) -
Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses
por: Jessica J. Harrison, et al.
Publicado: (2021) -
Erratum for Chen et al., “Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate”
por: Qi Chen, et al.
Publicado: (2019) -
Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis
por: Xuping Xie, et al.
Publicado: (2017)